IN8bio
Most recent annual filing: 2026-03-12
- INB-400 filing2H 2026INB-400 filing, 2H 2026, major
- INB-619 readout2H 2026INB-619 readout, 2H 2026, notable
- INB-200/INB-400 Ph2 interimMid- and Late-2026INB-200/INB-400 Ph2 interim, Mid- and Late-2026, major
- INB-100 enrollment doneLate 2026INB-100 enrollment done, Late 2026, notable
- Corporate financingApr 2027Corporate financing, Apr 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
DeltEx DRI
DeltEx · INB-200INB-400
INB-619
INB-300
- Undisclosed indication
INB-500
- Undisclosed indication
Technology platforms
DeltEx
Suite of gamma-delta T cell platform technologies encompassing TCEs, allogeneic, autologous, iPSC, and genetically modified cell therapy approaches designed to identify and eradicate tumor or target cells; applications in oncology and autoimmune diseases
INB-600
Novel gamma-delta T cell engager platform designed to selectively eliminate targets such as CD19, potentially reducing cytokine release syndrome and infections while expanding the therapeutic window compared with conventional CD3-targeting T cell engagers; applications across oncology and autoimmune indications
Targets: CD19
Biotech Distilled coverage (4)
- 2026-08-07 UPDATE: IN8bio (INAB) - The Science Is Winning. The Listing Is the Problem. 🔒 Paid
- 2026-07-09 UPDATE: IN8bio (INAB) - The JCO Stamp Lands, the Tape Ignores It
- 2026-06-02 UPDATE: IN8bio (INAB) - The Survival Curve Keeps Separating, and the ATM Spigot Just Turned On 🔒 Paid
- 2026-05-14 IN8bio (INAB) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.